{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:44:07Z","timestamp":1782729847459,"version":"3.54.5"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-07795-7","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:47:22Z","timestamp":1777711642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transitioning from clozapine to Cobenfy (xanomeline-trospium chloride) in treatment resistant schizophrenia and clozapine induced OCD"],"prefix":"10.1186","volume":"26","author":[{"given":"Ali","family":"Nakip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen F.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"2","key":"7795_CR1","doi-asserted-by":"publisher","first-page":"18com12123","DOI":"10.4088\/JCP.18com12123","volume":"80","author":"JM Kane","year":"2019","unstructured":"Kane JM, Agid O, Baldwin ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80(2):18com12123. https:\/\/doi.org\/10.4088\/JCP.18com12123.","journal-title":"J Clin Psychiatry"},{"key":"7795_CR2","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.KEBE.070415","author":"DL Kelly","year":"2015","unstructured":"Kelly DL, Ben-Yoav H, Payne GF, et al. Blood draw barriers for treatment with clozapine and development of point-of-care monitoring device. Clin Schizophr Relat Psychoses. 2015. https:\/\/doi.org\/10.3371\/CSRP.KEBE.070415.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"1","key":"7795_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/157015912799362779","volume":"10","author":"F Schirmbeck","year":"2012","unstructured":"Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol. 2012;10(1):88\u201395. https:\/\/doi.org\/10.2174\/157015912799362779.","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"7795_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2019.052","volume":"42","author":"N Keks","year":"2019","unstructured":"Keks N, Schwartz D, Hope J. Stopping and switching antipsychotic drugs. Aust Prescr. 2019;42(5):152\u20137. https:\/\/doi.org\/10.18773\/austprescr.2019.052.","journal-title":"Aust Prescr"},{"issue":"8","key":"7795_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.1149","volume":"81","author":"I Kaul","year":"2024","unstructured":"Kaul I, Correll CU, Marder SR, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024;81(8):749\u201356. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.1149.","journal-title":"JAMA Psychiatry"},{"key":"7795_CR6","unstructured":"Alva G. A clinical challenge: transitioning patients to Cobenfy. Psychiatric Times. 2025 Apr 11 [cited 2025 Sep 30]. Available from: https:\/\/www.psychiatrictimes.com\/view\/a-clinical-challenge-transitioning-patients-to-cobenfy."},{"key":"7795_CR7","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.eclinm.2025.103291","volume":"84","author":"M Samara","year":"2025","unstructured":"Samara M, Lappas AS, Pinioti E, et al. Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis. EClinicalMedicine. 2025;84:103291. Published 2025 Jun 7. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103291.","journal-title":"EClinicalMedicine"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-07795-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07795-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:45:17Z","timestamp":1782726317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-07795-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7795"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-07795-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient has provided written informed consent for their personal and clinical details. No identifying images are required for this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There were no competing interests at the time the patient care was established by the primary author and the manuscript was written\/reviewed by all authors. One month ago, Dr. Rachel Rose became a consultant for Bristol Myer Squibb, after the case was written.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"488"}}